What Флуоксетин-Канон treats: Main Uses and Benefits

This medication is used to assist in the management of symptoms associated with certain psychiatric conditions. The goal of using this agent is to help stabilize mood, and address manifestations of anxiety, tension, and fear, which can support overall well-being.

The medication is indicated for use in several clinical scenarios, including the treatment of major depressive disorder, obsessive-compulsive disorder, and bulimia nervosa. Medical specialists indicate that the agent may facilitate the reduction of distressing symptoms.

---

Quick Fact: Relief for Anxiety and Fear Manifestations

---

In clinical practice, this agent may be utilized to address signs such as persistent low mood, pathological preoccupation with repetitive thoughts or actions, and certain eating disorder symptoms. Symptom relief may become apparent after several weeks of application.

Eligibility Profile: Who Can and Cannot Use Флуоксетин-Канон

This information reflects the official eligibility rules and restrictions defined in government regulatory labeling for the active ingredient, Fluoxetine.

Classification	Population/Condition	Eligibility Status
Allowed	Adults (18+ years)	Approved for use across all labeled indications.
	Adolescents (8-18 years)	Approved for Major Depressive Disorder (MDD).
	Children (7-17 years)	Approved for Obsessive Compulsive Disorder (OCD).
Contraindicated	Patients with Known Hypersensitivity	Absolute prohibition.
	Concomitant use with MAOIs	Absolute prohibition.
	Concomitant use with Pimozide/Thioridazine	Absolute prohibition due to risk of cardiac effects.

---

Age and Condition-Based Restrictions

• Age Limits: Use is not established for MDD in patients under 8 years of age or for OCD in patients under 7 years of age. A lower or less frequent dose is recommended for Geriatric Patients (ge 65 years).
• Organ Function: Patients with Hepatic Impairment (e.g., cirrhosis) have restricted eligibility and require a lower or less frequent dose due to decreased drug clearance.
• Conditional Use: Caution is required for patients with a history of Seizures or conditions that increase the risk of QT Prolongation (cardiac risk factors). Screening for Bipolar Disorder is mandatory before treatment initiation.
• Reproductive Status: Use during Pregnancy is conditional, permitted only if the potential benefit justifies the potential risks. Breastfeeding is not recommended as the drug is secreted into human milk.

Interactions with other medicines and products

Official regulatory information for Fluoxetine (Флуоксетин-Канон) details specific drug and substance interactions, categorized by mechanism and resulting constraint.

Contraindicated Combinations & Timing Constraints

The co-administration of Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Thioridazine, and Linezolid is strictly contraindicated due to the risk of serious adverse reactions, including Serotonin Syndrome and QT prolongation. Mandatory timing constraints require a five-week washout period after discontinuing fluoxetine before initiating an MAOI, and a 14-day washout period after stopping an MAOI before starting fluoxetine.

Pharmacokinetic & Pharmacodynamic Interactions

Fluoxetine is documented as a potent inhibitor of the CYP2D6 enzyme. This pharmacokinetic property may lead to increased plasma concentrations of co-administered CYP2D6 substrates, such as Tricyclic Antidepressants (TCAs). Pharmacodynamic interactions are noted with other serotonergic medicinal products (e.g., Triptans, Tramadol, Lithium), which increase the documented risk of Serotonin Syndrome. Co-administration with agents affecting hemostasis (e.g., NSAIDs, Warfarin) is associated with an increased risk of bleeding events.

Substance and Population Notes

The co-use of alcohol is not recommended, and the herbal product St. John's Wort is noted to increase serotonergic effects. Interaction effects may be more pronounced in hepatic impairment due to reduced clearance.

The drug’s primary action is the selective inhibition of the Serotonin Transporter ( SERT) protein on nerve cell membranes. By blocking this specific transport mechanism, Fluoxetine prevents the reabsorption of the neurotransmitter serotonin ( 5-HT) back into the neuron, immediately increasing the concentration and duration of 5-HT signaling in the synaptic cleft.

The full physiological effect is a result of neuronal adaptation that occurs after the initial SERT blockade. The sustained high level of 5-HT in the synapse triggers the desensitization of inhibitory 5-HT autoreceptors over several weeks, which gradually removes the self-regulating brake on 5-HT release. This long-term adaptation ultimately alters function within the CNS circuits responsible for serotonergic signaling and regulation.

Furthermore, the mechanism is sustained and prolonged by the drug’s principal transformation product, Norfluoxetine, which is itself an active and selective SERT inhibitor. Because the metabolite remains active in the system for a long duration, it ensures the consistent and continuous SERT blockade required for the CNS adaptation pathways to fully consolidate and maintain homeostatic equilibrium.

How to Use Флуоксетин-Канон

The administration of fluoxetine follows specific instructions for use. The medication is designated solely for oral use via immediate-release capsules, tablets, or a liquid solution.

Standard use generally follows a once-daily schedule, typically administered in the morning. Dosing is structured around the indication, with a common adult starting dose of 20 mg daily. The standard maintenance range extends from 20 mg to 60 mg daily, with a maximum daily dose of 80 mg for certain indications. For Bulimia Nervosa, the target dose is established as 60 mg once daily. The medicine may be taken with or without food.

Population and Duration Guidelines

Dose modifications are utilized for specific groups. A lower or less frequent dosage is generally necessary for older adults, whose daily dose should not exceed 60 mg, and for patients with hepatic impairment, where alternate day dosing may be considered. When using the liquid form, precise measurement with a calibrated device is necessary.

The procedural structure of treatment requires maintaining the dose for several weeks before adjustments are considered, reflecting the drug's long time-to-effect. Continuation of therapy for Major Depressive Disorder is often guided to last at least six months following a sufficient response. Due to the long half-life of the drug and its active metabolite, formal dose tapering upon discontinuation is often unnecessary for most patients.

Research evidence / Overview of Studies for Флуоксетин-Канон

---

Evidence for Use in Major Depressive Disorder (MDD)

Research has explored the effects of Fluoxetine in settings related to conditions characterized by persistent low mood and functional limitations. Studies conducted during periods of increased symptom activity include short-term Randomized Controlled Trials (RCTs), where individuals receiving the medicine were compared against a placebo. These trials, typically lasting 4 to 12 weeks, were used in research exploring acute symptom changes. Findings describe patterns observed in the studies regarding measured changes in the severity of depressive symptoms. Other research monitored responses over defined time intervals of up to one year to examine the time until the return of symptoms. However, certainty remains limited when considering the full extent of the difference observed between the medicine and placebo in all meta-analyses, where the overall magnitude of the measured change is sometimes described as modest.

---

Evidence for Use in Obsessive-Compulsive Disorder (OCD) and Panic Disorder

This medicine was studied for its application in conditions involving periods of heightened symptoms, such as OCD and Panic Disorder. For OCD, research explored outcomes describing changes in obsessive and compulsive symptom severity over observation periods typically lasting 8 to 12 weeks. For Panic Disorder, studies monitored the frequency of episodic or acute changes, specifically the number of panic attacks, over short-term intervals. While research provides insight into short-term changes, evidence is limited regarding the long-term patterns following discontinuation of the agent, especially concerning the potential for symptom reemergence.

---

Evidence in Specific Patient Groups and Research Gaps

Studies focusing on MDD and OCD included separate pediatric populations (children and adolescents), meaning the research examined how the measured outcomes evolved in these specific age ranges. Findings describe group patterns, but results apply only to the populations studied. The evidence for other groups, such as some older adults and patients with certain co-occurring conditions, is limited. As noted, long-term effects are not fully established, and there is limited information for outcomes beyond one year of observation across all uses. Research exploring symptom changes often describes that sample sizes were modest in specific trials, and evidence quality varies across studies.

Key Studies & References

1. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression
2. TRANSPARENCY COMMITTEE - Medical, Economic and Public Health Assessment Division (Includes Bulimia Nervosa relapse prevention trial summary)

Common questions about Флуоксетин-Канон (FAQ)

Q: What is Флуоксетин-Канон prescribed for?

Official product information states that Fluoxetine is approved to support treatment for several conditions. These indications include Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, and Bulimia Nervosa.

---

Q: How can I tell if Флуоксетин-Канон has started working?

Studies and official information indicate that improvement is gradual, often requiring several weeks for the full effect to become apparent. Efficacy is typically measured by changes in the severity of symptoms, such as the reduction of depressive symptoms or a decrease in the frequency of panic attacks.

---

Q: What are the early side effects of Флуоксетин-Канон in the first few days of taking it?

Regulatory documents classify certain effects as Very Common, which often manifest early, including insomnia, headache, diarrhea, nausea, and fatigue. Official safety statements emphasize that an increased risk of suicidal ideation is most frequently associated with the initial weeks of treatment or following a change in dosage.

---

Q: Do I need to have medical tests before starting Флуоксетин-Канон?

Official product information notes that screening for Bipolar Disorder is necessary before initiating treatment with Fluoxetine. Additionally, caution is advised for patients with certain heart issues, such as risk factors for QT prolongation, which may require medical evaluation prior to use.

---

Q: What are the main differences between Флуоксетин-Канон and other antidepressants?

Флуоксетин-Канон belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class of antidepressants. Its action is distinct due to the uniquely long half-life of its active metabolite, norfluoxetine, which contributes to the prolonged presence of the active substance in the body. Regulatory documents also note that it acts as a potent inhibitor of the CYP2D6 enzyme.

---

Q: If Флуоксетин-Канон didn't work, can I switch to another drug immediately?

Due to the long duration of the active substance in the body, official regulatory guidelines advise caution when switching medications. Regulatory documents indicate a necessary timing constraint, such as a washout period of up to five weeks before initiating certain other treatments, like Monoamine Oxidase Inhibitors (MAOIs).

---

Q: What is in Флуоксетин-Канон besides the active substance?

The medicine contains the active substance, Fluoxetine Hydrochloride, but official product descriptions also list various excipients. Excipients are the inactive ingredients included in the formulation, such such as binding agents, coloring, or fillers.

---

Q: Why does the leaflet mention 'withdrawal syndrome' upon discontinuation?

Regulatory documents typically refer to symptoms experienced after stopping treatment as 'discontinuation symptoms' or 'adverse events upon discontinuation.' However, due to the drug's long half-life, official documents note that a formal dose tapering (gradually lowering the dose) is often not considered necessary for most patients.

---

Q: Is Флуоксетин-Канон indicated for the treatment of anxiety disorders?

Fluoxetine is officially approved for specific anxiety-related conditions, namely Obsessive Compulsive Disorder (OCD) and Panic Disorder. Regulatory documentation does not list approval for Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder.

---

Q: What is 'Serotonin Syndrome' and how is it related to Флуоксетин-Канон?

Serotonin Syndrome is a rare, potentially life-threatening reaction associated with increased serotonin levels, which is a risk when taking Fluoxetine. Official safety warnings describe this condition as involving symptoms like changes in mental status, elevated body temperature (hyperthermia), and neuromuscular abnormalities such as tremors or overactive reflexes.

---

Q: Is there a difference in effect between Флуоксетин-Канон and original fluoxetine?

Generic drug manufacturers must meet regulatory standards that demonstrate bioequivalence to the original brand product. This means that, according to official guidelines, the generic and brand versions are required to deliver the same amount of active ingredient to the bloodstream over the same time period, with the regulatory objective of achieving equivalent therapeutic effects.

---

Q: Can Флуоксетин-Канон affect my weight?

Regulatory documents list changes in weight as a possible adverse reaction. This includes both weight gain and weight loss.

---

Q: Is it true that Флуоксетин-Канон can cause loss of appetite?

Yes, regulatory documents list decreased appetite as a Common adverse reaction. This means it is an effect reported by at least 1 in 100 patients in clinical settings.

---

Q: Am I allowed to drive while taking Флуоксетин-Канон?

Official documents caution that the medicine may impair the ability to operate machinery, which includes driving. This caution is due to potential adverse effects like fatigue, dizziness, or somnolence that can occur while using the medication.

---

Q: Is Флуоксетин-Канон the same as Prozac?

Флуоксетин-Канон contains Fluoxetine Hydrochloride, which is the generic name for the active substance. The drug originally marketed under the brand name Prozac also contains Fluoxetine.

---

Q: Is Флуоксетин-Канон habit-forming?

Public health sources generally describe Fluoxetine as having no known potential for physical dependence or abuse. It is not classified as a controlled substance.

---

Q: Does Флуоксетин-Канон affect attention and memory?

Yes, regulatory safety documents list adverse reactions related to the nervous system, including impaired attention and memory impairment.

---

Q: Does Флуоксетин-Канон affect blood pressure?

Official safety documents list adverse reactions related to the cardiovascular system. This includes both hypotension (low blood pressure) and hypertension (high blood pressure).

Storage and Disposal Requirements for Fluoxetine

The storage and disposal of Fluoxetine (Флуоксетин-Канон) must follow specific regulatory guidelines to maintain product stability and safety.

Storage Conditions

Item	Requirement
Temperature	Store at a temperature not exceeding 25°C (77°F) (room temperature).
Protection	Keep the medicine protected from light and excess moisture and heat.
Container	Store in the original container and keep it tightly closed.
Child Safety	The medicine must be kept out of the sight and reach of children.

---

Disposal Instructions

Disposal of unused or expired product must be according to local regulations. The preferred method is a formal drug take-back program. Fluoxetine is not on the official FDA flush list. If a take-back program is unavailable, mix the medicine with an undesirable substance (e.g., dirt) and seal it in a bag before placing it in the household trash. Scratch out all personal information on the label before discarding the container.